From Awareness Days to Year-Round Action: Evolving Disease Campaigns for Lasting Impact
Each year, awareness days flood our social feeds with ribbons, hashtags, and heartfelt stories. Yet by the next month, the momentum often fades. This...
Competing for the Patient Relationship: What Pharma Can Learn from Digital Health Startups
As the healthcare industry embraces digital transformation, digital health partnerships are becoming essential to how patients experience care. Virtual care platforms, wearable technologies, and...
Marketing in the Gray Zone: Launching with Conditional Approvals and Incomplete Data
Accelerated and conditional drug approvals often bring early market access—but also evolving data and heightened regulatory sensitivity. This article explores how marketers can build...
Pharmacists at the Frontline: Why the Retail HCP Deserves a New Marketing Strategy
Pharmacists are playing an expanding role in vaccine delivery, chronic care, and therapeutic recommendations—yet most pharma campaigns treat them as an afterthought. This article...
Lead With Access: Why Pharma Campaigns Should Start With Coverage, Not Brand Awareness
Payer-first pharma marketing is transforming how pharmaceutical brands connect with patients and providers. While traditional campaigns often focus on brand awareness or disease education,...
Real-Time Risk: What Safety Bulletins Mean for Omnichannel Brand Perception
In the fast-moving world of healthcare marketing, the ability to respond swiftly and strategically to regulatory updates has never been more important. As the...
Pricing Politics and Pharma Messaging: Preparing Brands for the Post-IRA Landscape
The Inflation Reduction Act (IRA) has sparked one of the most significant transformations in the U.S. pharmaceutical landscape in decades. As pricing negotiations and...
EU Pharma Reform and the Marketing Fallout: Adapting to a New Regulatory Playbook
The EU pharma reform is reshaping how pharmaceutical companies approach innovation, market access, and marketing...
Rethinking Drug Pricing Communication: Communicating Value Beyond the Sticker Price
As public scrutiny and policy shifts continue to focus on pharmaceutical pricing, the list price of a drug often fails to reflect what patients,...
When Pharma Becomes a Punchline: Crisis Readiness in the Misinformation Age
Today, even the most science-backed pharma brands are just one meme or tweet away from a reputational firestorm. Whether it’s a conspiracy theory, a...
